Wednesday, 10 October 2018

Diabetes linked to higher risk of getting cancer and dying from it




Diabetes is a group of diseases that result in too much sugar in the blood (high blood glucose). Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period. Symptoms of high blood sugar include frequent urination, increased thirst, and increased hunger.

People with diabetes are at greater risk of developing and dying from cancer, according to new research.

The findings emerged from two separate studies presented at this year’s “European Association for the Study of Diabetes annual meeting”.

A UK study by the University of Manchester found people with type 2 diabetes were at greater risk of dying from cancer – especially when it came to obesity-related cancers such as bowel, kidney and pancreatic cancer or breast and endometrial cancer in women. Researchers compared data on 176,886 people with type 2 diabetes from the UK Practice Research Datalink with a matched control group of nearly 853,000 people without diabetes.

The study, which looked at 13 types of cancer, suggested men with type 2 diabetes were 22% more likely to die from any cancer than those without diabetes. For women the risk was 31% higher. There were evidence people with diabetes had a reduced risk of prostate cancer compared to those without diabetes, but mortality rates from prostate cancer and colon cancer were higher. Nevertheless, the study authors were keen to stress the absolute risk of cancer was still low. They have compared the results if Normal person with the diabetes Over a 10-year period, they noted a 38% greater increase in new cases of pancreatic cancer among diabetics, compared to non-diabetics, and a 30% greater increase in lung cancer incidence.


Monday, 24 September 2018

5th World Nursing and Nursing Care Congress: The anti-smooth muscle antibody test

5th World Nursing and Nursing Care Congress: The anti-smooth muscle antibody test: An anti-smooth muscle antibody (ASMA) test detects antibodies that attack smooth muscle. This test requires a blood sample. Yo...

The anti-smooth muscle antibody test




An anti-smooth muscle antibody (ASMA) test detects antibodies that attack smooth muscle. This test requires a blood sample.

Your immune system detects substances called antigens that may be harmful to your body. Viruses and bacteria are covered with antigens. When your immune system recognizes an antigen, it makes a protein called an antibody to attack it.
Every antibody is unique, and each one defends against only one type of antigen. Sometimes your body mistakenly makes autoantibodies, which are antibodies that attack your body’s own healthy cells. If your body starts attacking itself, you may develop an autoimmune disorder.

The smooth muscle (SMA) or actin antibody test is primarily ordered along with antinuclear antibodies (ANA) and liver kidney microsomal type 1 (LKM-1) antibodies to help diagnose autoimmune hepatitis and to differentiate between the two major types of autoimmune hepatitis, type 1 and type 2.

Risks:

In very rare cases, having blood drawn may result in:
  1.        Excessive bleeding
  2.         Lightheadedness or fainting
  3.         A hematoma, which is an accumulation of blood under the skin
  4.         An infection at the needle site


There are two tests can be taken for the diagnosis. They are

     1.Normal Test
     2.Abnormal Test

Outlook:

The ASMA test is a low-risk procedure similar to any routine blood test.

The doctor's office sends the blood sample to a lab. A lab technician will analyse the levels of ASMA in the blood and return results.

The ASMA test can help a doctor to diagnose autoimmune disorders in the liver and other conditions.

If ASMA levels are high, the doctor may request additional testing before making a diagnosis and recommending a course of treatment.






Thursday, 20 September 2018

NURSING CARE CONGRESS 2019

About Conference


PULSUS takes immense pleasure in inviting all the participants from across the globe to attend 5th World Nursing and Nursing care Congress during March 11- 12, 2019 in Orlando, USA. This comprises of proficient keynote presentations, verbal speeches, productive poster presentations and exhibitions providing insights to the importance and efficiency of nursing in Healthcare.

Pulsus Group is an internationally renowned peer-review publisher in scientific, technical, and medical journals established in the year 1984 with offices in Ontario, Canada and Hyderabad, India has acquired Andrew John Publishing and openaccessjournals.com to expand its Open Access Publishing through its 50+ journals in association with 20+ International medical and scientific societies.

Nursing Care Congress 2019 Conference highlights the theme Innovative Approaches in Nursing Practice and Nursing Care is an event intended to provide an exclusive platform for new researchers, scholars, nurses, surgeons, physicians, students and educators to show case their novel ideas and discuss the most recent innovations, trends and key concerns adopted in the field of nursing and health care. The two days of educational program will include keynote presentations, oral presentations, and poster presenters on the advanced techniques as well as papers in all the fields of nursing in health care. Nursing Care Congress 2019 Conference aims to explore advances in nursing practice, management and education in relation to health disparities as well as a breadth of other topics.Nursing Care Congress 2019 will provide an opportunity for nursing practitioners and educators to exchange research evidence, models of best practice and innovative ideas. It is a platform for nursing students, faculty, deans, researchers, and leaders to collaborate on topics affecting nursing education.

Attendees can:
  • Take advantage of opportunities to learn insights about Nursing and Health Care from a variety of oral and poster presentations.  
  • Meet and network with nurses ranging from students to deans, faculty, and researchers.
  • Take advantage of opportunities to collaborate with nurses from around the world.
Attend prominent plenary sessions about relevant issues affecting nursing care and the recent techniques adapted in nursing care



Conference Highlights



Special Issues


  •  All accepted abstracts will be published in respective Supporting International Journals.
  •  Abstracts will be provided with Digital Object Identifier by Cross Ref.

Monday, 10 September 2018

Nursing Care Congress 2019 #March 11-12 #Orlando #USA

Its time to present your research work and to share your thoughts regarding the Nursing Care.

                                                  SPEAKER SLOTS 
                                                    
                                                    AVAILABLE!!!


Few list of experts and their presentations are:

Name: Manar Jabbar 
            University of Mosul
            Iraq

Abstract Title: Modern and latest treatment of fibroid

Name : Yuki Kamada
               Saga University
               Japan 

Abstract Title: A basic study to develop a self-evaluation scale of outreach activity implementation by multidisciplinary teams for persons with mental health concerns

and many more...

Nursing Care Congress 2019 Conference highlights the theme Innovative Approaches in Nursing Practice and Nursing Care is an event intended to provide an exclusive platform for new researchers, scholars, nurses, surgeons, physicians, students and educators to show case their novel ideas and discuss the most recent innovations, trends and key concerns adopted in the field of nursing and health care. The two days of educational program will include keynote presentations, oral presentations, and poster presenters on the advanced techniques as well as papers in all the fields of nursing in health care.

For more details: https://worldnursing.pulsusconference.com/



Thursday, 6 September 2018

Ovarian cancer: Scientists find a way to launch dual attack



Ovarian Cancer is a 5th most common cause of deaths in Women. Ovarian cancer is a disease with a poor prognosis and little progress has been made to improve treatment. It is now recognized that there are several histotypes of ovarian cancer, each with distinct epidemiologic and genomic characteristics. Cancer therapy is moving beyond classical chemotherapy to include epigenetic approaches.

“This Article was published on September 3 in the Medical News by the Autor Catharine Paddock PhD”
His study states that the Two Targets hitting on the cancer cells could gently increase the power of antibody therapy to kill the Ovarian Cancer-causing cells.

Antibody Therapy (Mostly monoclonal antibody therapy) is the type of Immune therapy or immune therapy in this therapeutic method the antibodies will bind mono specifically to the protein or certain cells in the immune system.  It will help to stimulate the immune system of the patient who are all fighting against to the Ovarian cancer cells

Alternatively, Radioimmunotherapy Is the radioactive dose that will localizes the cell line delivering lethal chemical doses, that uses enhanced anti bodies to identify diseases targets and kill them. It is success in treating the Ovarian Cancer and solid tumors.

The hostile microenvironment of the tumor which makes it hard for antibodies designed to kill cancer cells to reach them.
They were approaching the “two-pronged" antibody that will hit the two-target antibody on the Ovarian Cancer Cell.

Ovarian cancer and immunotherapy
Some of the Therapies use the antibodies as a Markers that the other immune cells can easily spot their targets and destroy the cancer cells. Ovarian Cancer forms solid tumors that means the malignant growth do not usually contain liquid or cysts.

Antibodies with Two Heads
The researchers focused on how to overcome the hostility of the Microenvironment. This is how they came up with the idea of antibodies with two heads
For more details regarding the nursing updates:  https://worldnursing.pulsusconference.com/

Tuesday, 28 August 2018

FDA approves first generic version of EpiPen



The Food and Drug Administration approved the first generic version of EpiPen on Thursday, a move that will bring new competition for the lifesaving allergy injection that helped spark public furor over high drug prices.

The new drug, from Teva Pharmaceuticals USA, is the first to be deemed a therapeutic equivalent of the EpiPen, which means that it can be automatically substituted at the pharmacy counter for prescriptions for EpiPen or EpiPen Jr.

The approval comes right before the back-to-school season, when sales of EpiPen typically spike as parents stock up on injectors for school or replace expired ones, and people have reported difficulty filling EpiPen prescriptions. There has been “limited availability of EpiPen in certain areas in the U.S., including both pharmacy-level supply disruptions and a manufacturer issue,” according to FDA spokeswoman Theresa Eisenman.

The EpiPen, made by Mylan, is used to inject the hormone epinephrine into the thigh to quell potentially fatal reactions to bee stings, peanuts and other allergens. Although the key ingredient is cheap and the EpiPen itself was first approved in 1987, Mylan began increasing the price of the product, from less than $100 in 2007 for a pack of two injectors to $608 today. In response to criticism over the price of its drug, EpiPen introduced its own half-priced generic in 2016.

Formore details regarding Nursing news, do visit: https://worldnursing.pulsusconference.com/